Inviragen, University of Texas Medical Branch deal

The university granted partner Inviragen exclusive, worldwide rights to a chikungunya virus (CHIKV) vaccine. The recombinant CHIKV vaccine constructed by making defined alterations in the regions of the CHIKV genome that control viral gene expression is in preclinical testing. The parties were developing the vaccine under a 2005 deal. Terms were not disclosed. ...